Ovoca Bio (OVXA) H1 2025 earnings summary

Executive summary

• Reported a total comprehensive loss of €1.24 million for the six months ended 30 June 2025, compared to €1.34 million loss in the same period last year.

• Discontinued biopharmaceutical operations in Australia, with a focus on exploring alternative business opportunities and restructuring.

• No dividends were distributed during the period.

Financial highlights

• Loss for the period from continuing operations was €1.17 million, with a total loss for the period of €1.24 million.

• Basic loss per share from continuing operations was €1.32, and from discontinued operations €0.45.

• Net cash used in operating activities was €0.95 million, with a net decrease in cash and cash equivalents of €0.98 million.

• Cash and cash equivalents at period end were €1.53 million.

Outlook and guidance

• Management is focused on ensuring continuity, long-term viability, and exploring M&A or asset sale opportunities.

• The board continues to seek value realization for shareholders and to address economic challenges.